Brand vs Compounded vs Generic Cost Comparison
Last reviewed: April 2026
A GLP-1 savings calculator estimates the monthly and annual cost of GLP-1 receptor agonist medications like semaglutide and tirzepatide, comparing brand-name, compounded, and insurance-covered pricing. It helps patients understand their out-of-pocket expenses across different sourcing options.
GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become the most talked-about medications in healthcare. They are proven to help with both type 2 diabetes management and significant weight loss (15–25% of body weight in clinical trials). But the cost is a major barrier: brand-name GLP-1s run $900–$1,700 per month without insurance, making them among the most expensive chronic medications available. This calculator compares your options side by side so you can make an informed decision about which route to take. Track the health impact alongside cost with our BMI Calculator and Blood Sugar Converter.
Brand-name GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved with extensive clinical trial data. They cost $900–$1,700/month at list price, though manufacturer savings programs and insurance can reduce this significantly. Compounded versions of semaglutide are made by compounding pharmacies at $150–$500/month — much cheaper, but not FDA-approved, and quality varies between pharmacies. The FDA has issued warnings about some compounded GLP-1 products. True generic semaglutide is not yet available in the US. Evaluate the financial impact over time with our Budget Calculator.
Insurance coverage for GLP-1s varies dramatically. Many plans cover semaglutide for diabetes (Ozempic) but not for weight loss (Wegovy). Employer plans increasingly cover weight-loss indications, but Medicare does not (as of 2026, though legislation is pending). Novo Nordisk and Eli Lilly both offer savings cards that can reduce copays to $25–$50/month for commercially insured patients. For uninsured patients, patient assistance programs may provide the medication free if you meet income requirements. Compare your prescription costs to your overall healthcare spending with our HSA Calculator.
| Medication | List Price/Month | With Insurance | Savings Program |
|---|---|---|---|
| Ozempic (semaglutide) | $900–$1,000 | $25–$300 | Manufacturer savings card |
| Wegovy (semaglutide) | $1,300–$1,400 | $0–$500 | Limited coverage |
| Mounjaro (tirzepatide) | $1,000–$1,100 | $25–$300 | Manufacturer savings card |
| Compounded semaglutide | $150–$500 | Usually not covered | Cash pay |
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are among the most expensive prescription medications in the United States. Without insurance, brand-name GLP-1 medications like Ozempic and Wegovy cost approximately $900–$1,400 per month, while Mounjaro ranges from $1,000–$1,200 per month. With commercial insurance and manufacturer coupons, out-of-pocket costs can drop to $25–$500 per month depending on your plan's formulary and tier placement. Medicare Part D covers some GLP-1 medications for diabetes but has historically excluded weight-loss indications, though this is evolving under the Inflation Reduction Act's provisions. The total annual cost without assistance ranges from $10,800 to $16,800 — making the financial decision to start (or continue) GLP-1 therapy a significant budget consideration.
| Access Method | Monthly Cost Range | Annual Cost |
|---|---|---|
| Cash price (no insurance) | $900–$1,400 | $10,800–$16,800 |
| Commercial insurance (preferred tier) | $25–$150 | $300–$1,800 |
| Commercial insurance (non-preferred) | $200–$500 | $2,400–$6,000 |
| Manufacturer savings card | $0–$25 (with eligible insurance) | $0–$300 |
| Compounding pharmacy | $150–$500 | $1,800–$6,000 |
While GLP-1 medications are expensive, they can generate significant savings elsewhere. Patients who achieve meaningful weight loss (10–15%+) often see reductions in other medication costs (diabetes drugs, blood pressure medications, statins), fewer doctor visits and medical procedures, lower life insurance premiums, reduced food spending (appetite suppression typically reduces grocery bills by $100–$200/month), and avoidance of obesity-related surgeries and hospitalizations. A comprehensive cost-benefit analysis compares the medication cost against these combined savings. For a patient spending $300/month on diabetes medications, $150/month on blood pressure drugs, and $200/month in excess food costs, the net cost of a $250/month GLP-1 medication is effectively negative — it saves money overall.
If your insurance does not cover GLP-1 medications or places them on a high-cost tier, several strategies can help. First, ask your doctor to submit a prior authorization with clinical documentation supporting medical necessity. Second, appeal any denial in writing — success rates on first appeal range from 30–50%. Third, check manufacturer patient assistance programs: Novo Nordisk and Eli Lilly both offer programs for eligible patients. Fourth, consider whether switching to a different insurer during open enrollment would provide better coverage. Fifth, if using for weight management, obtain documentation of BMI and at least one weight-related comorbidity, as this strengthens coverage arguments. Track your overall healthcare costs with our Health Insurance Calculator.
Sustained weight loss of 10–15% reduces lifetime healthcare costs by an estimated $15,000–$40,000 per person, primarily through reduced rates of type 2 diabetes, cardiovascular disease, joint replacements, sleep apnea treatment, and certain cancers. Life insurance premiums can decrease significantly — a person moving from obese (BMI 35) to overweight (BMI 28) BMI classification may see premium reductions of 20–40%. Disability insurance costs similarly decline. While GLP-1 medications may need to be continued long-term to maintain weight loss, the health cost savings often exceed the medication cost for patients with obesity-related conditions. Calculate your BMI and health metrics with our BMI Calculator and model your overall weight loss with our GLP-1 Weight Loss Calculator.
Compounding pharmacies can produce custom formulations of semaglutide at significantly lower prices — typically $150–$500/month compared to $900–$1,400 for brand-name products. These compounded versions use the same active ingredient but are not FDA-approved products — they are permitted under FDA guidance when there is a drug shortage. The quality, dosing accuracy, and sterility vary by pharmacy, making it important to use accredited compounding pharmacies (look for PCAB accreditation). Discuss compounding options with your healthcare provider, as they may have preferred compounding pharmacy partners. Factor the medication cost into your overall budget with our Budget Calculator.
The rapid adoption of GLP-1 medications has significant implications for healthcare spending and outcomes at scale. If 10% of the estimated 100 million eligible Americans with obesity or diabetes used GLP-1 medications, the annual pharmacy cost would exceed $100 billion — potentially unsustainable for insurance systems. However, the downstream savings from reduced hospitalizations, surgeries (bariatric, joint replacement, cardiovascular), and chronic disease management could offset a substantial portion. Ongoing research and real-world evidence will determine the long-term cost-effectiveness equation. For individual patients, the decision is more straightforward: compare your personal medication cost against your specific health improvements and reduced medical expenses using this calculator.
Bariatric surgery (gastric bypass, gastric sleeve) produces larger average weight loss (25–35%) than GLP-1 medications (15–22%) and costs $20,000–$35,000 as a one-time expense. Over 5 years, surgery is often less expensive than continuous GLP-1 therapy. However, surgery carries surgical risks, requires permanent dietary changes, and is irreversible. GLP-1 medications are non-invasive, adjustable, and can be discontinued — but weight typically returns when medication stops. Intensive lifestyle intervention programs cost $2,000–$5,000 annually but produce modest average weight loss (5–7%). The optimal choice depends on individual circumstances, health status, and financial resources. Track your weight loss progress with our Calorie Deficit Calculator and Ideal Weight Calculator.
While GLP-1 medications carry significant monthly costs ($800-$1,600 without insurance for brand-name versions), the downstream healthcare savings from sustained weight loss can be substantial. Obesity-related healthcare costs average $1,861 more per year than normal-weight individuals, and these costs escalate significantly with comorbidities: type 2 diabetes adds approximately $9,600/year in medical costs, cardiovascular disease adds $12,000-$18,000/year, and obstructive sleep apnea treatment costs $1,000-$3,000/year for CPAP supplies and monitoring. Clinical trials have demonstrated that GLP-1 medications reduce the risk of major adverse cardiovascular events by 20%, reduce the incidence of type 2 diabetes onset by 70-80% in prediabetic patients, and improve or resolve sleep apnea in over 40% of users. The break-even analysis for uninsured patients depends on which comorbidities are prevented or improved — preventing a diabetes diagnosis alone saves enough in lifetime medical costs (average $160,000) to justify several years of GLP-1 medication costs.
See also: BMI Calculator · Blood Sugar Converter · Calorie Calculator · HSA Calculator · Budget Calculator
→ Brand-name GLP-1s cost $900–$1,350/month without insurance. Ozempic and Wegovy (semaglutide) list at ~$900–$1,350. Mounjaro/Zepbound (tirzepatide) list similarly. With good commercial insurance, copays range from $25–$150/month. Medicare Part D coverage varies and may have restrictions.
→ Compounded semaglutide is significantly cheaper. Licensed compounding pharmacies offer semaglutide at $150–$400/month. Quality and dosing accuracy vary between pharmacies — choose a pharmacy accredited by PCAB or licensed in your state. FDA has raised concerns about some compounders.
→ Manufacturer savings cards can reduce costs dramatically. Novo Nordisk and Eli Lilly offer savings programs that can bring commercially insured copays down to $0–$25/month. These typically don't apply to government insurance (Medicare, Medicaid, Tricare).
→ Calculate the total investment over your treatment arc. A 12-month course at $300/month = $3,600. Consider whether weight-related health improvements (reduced medications, fewer doctor visits, better labs) offset the cost. See our GLP-1 Weight Loss Projector and Health Insurance Calculator.
See also: GLP-1 Weight Loss · GLP-1 Titration · Supplement Cost · Budget Calculator
GLP-1 receptor agonist medications carry list prices ranging from $900 to $1,350 per month, making insurance coverage a critical factor in affordability. Coverage varies widely by plan type and indication: most commercial insurance plans cover GLP-1 medications for type 2 diabetes management but may deny coverage for weight management alone, even when medically indicated. Medicare Part D covers GLP-1 drugs for diabetes but historically excluded weight-loss indications — a policy that has faced increasing legislative pressure to change. Prior authorization requirements are nearly universal and typically require documentation of failed diet and exercise attempts, BMI thresholds, and sometimes failed trials of older medications.
Several strategies can reduce out-of-pocket costs significantly. Manufacturer copay cards and patient assistance programs can reduce costs by $100 to $500 per month for commercially insured patients, though they typically do not apply to government insurance programs. Compounding pharmacies offer compounded versions of some GLP-1 medications at 60 to 80 percent lower cost during FDA-acknowledged shortage periods, though quality, bioequivalence, and legal status vary. Step therapy protocols may require trying less expensive medications first (such as metformin or older GLP-1 formulations) before insurance approves newer, more expensive options. Working with your prescriber to submit a detailed letter of medical necessity — including comorbidities, previous treatment failures, and clinical rationale — significantly improves approval rates on appeal.